In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 1.59 below Exact Sciences Corporation average.

Within Medical Laboratories industry 10 other companies have achieved higher Quick Ratio than Exact Sciences in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 341 to 710.

Explain Quick Ratio?
How much Cash & cash equivalents EXAS�s has?
What are EXAS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

EXAS Quick Ratio	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-13.79 %	-20.69 %	-23.53 %	-31.01 %	45.22 %
Y / Y Cash & cash equivalent Change	-7.06 %	-1.77 %	-9.33 %	20.56 %	33.48 %
Quick Ratio MRQ	1.59	1.82	1.75	1.66	1.47
EXAS's Total Ranking	# 710	# 341	# 595	# 636	# 304
Seq. Current Liabilities Change	9.98 %	12.6 %	3.8 %	-32.94 %	1.19 %
Seq. Cash & cash equivalent Change	-3.83 %	16.85 %	9.19 %	-24.26 %	1.65 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Medical Laboratories Industry	# 11
Healthcare Sector	# 250
Overall Market	# 710

Quick Ratio Statistics
High	Average	Low
23.91	7.58	0.95
(Jun 30 2014)		(Mar 31 2024)

Financial Statements
Exact Sciences's Current Liabilities	$ 608 Millions	Visit EXAS's Balance sheet
Exact Sciences's Cash & cash equivalent	$ 965 Millions	Visit EXAS's Balance sheet
Source of EXAS's Sales		Visit EXAS's Sales by Geography

Cumulative Exact Sciences's Quick Ratio

EXAS's Quick Ratio for the trailling 12 Months

EXAS Quick Ratio	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-22.17 %	-11.48 %	4.71 %	21.24 %	57.96 %
Y / Y Cash & cash equivalent TTM Growth	-1.25 %	8.48 %	19.06 %	28.99 %	22.49 %
Quick Ratio TTM	1.7	1.66	1.57	1.51	1.34
Total Ranking TTM	# 1956	# 1204	# 1799	# 2897	# 3302
Seq. Current Liabilities TTM Growth	-4.38 %	-6.09 %	-6 %	-7.79 %	8.75 %
Seq. Cash & cash equivalent TTM Growth	-1.99 %	-0.49 %	-2.33 %	3.67 %	7.66 %

Quick ratio ranking by company, industry and sector >> Back to EXAS Financial Strength Comparisons >> Go to Compare EXAS Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Exact Sciences's average Cash & cash equivalent, this led to increase in in Exact Sciences's Quick Ratio to 1.7, Quick Ratio remained below EXAS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 22 other companies have achieved higher Quick Ratio than Exact Sciences. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 1204 to 1956.

Explain Quick Ratio?
How much Cash & cash equivalents EXAS�s has?
What are EXAS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 23
Healthcare Sector	# 415
Within the Market	# 1956

trailing twelve months Quick Ratio Statistics
High	Average	Low
18	6.09	1.3
(June 30. 2014)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Medical Laboratories Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Castle Biosciences Inc	4.36	$ 299.505 Millions	$ 68.677 Millions
Guardant Health Inc	3.97	$ 1,201.598 Millions	$ 302.730 Millions
Fulgent Genetics Inc	3.96	$ 336.077 Millions	$ 84.967 Millions
Nano X Imaging Ltd	3.28	$ 59.610 Millions	$ 18.148 Millions
Grail Inc	3.13	$ 249.727 Millions	$ 79.670 Millions
Hologic Inc	2.49	$ 2,364.700 Millions	$ 947.800 Millions
Exagen Inc	2.28	$ 32.220 Millions	$ 14.159 Millions
Caredx Inc	2.24	$ 201.329 Millions	$ 89.849 Millions
Butterfly Network Inc	2.23	$ 150.489 Millions	$ 67.595 Millions
Bioaffinity Technologies Inc	2.22	$ 6.450 Millions	$ 2.906 Millions
Incyte Corporation	2.04	$ 3,097.817 Millions	$ 1,519.925 Millions
Burning Rock Biotech Limited	1.95	$ 68.752 Millions	$ 35.179 Millions
Sera Prognostics Inc	1.62	$ 39.201 Millions	$ 24.188 Millions
Exact Sciences Corporation	1.59	$ 964.711 Millions	$ 607.561 Millions
Radnet Inc	1.38	$ 807.504 Millions	$ 586.763 Millions
Ispecimen inc	1.11	$ 6.893 Millions	$ 6.231 Millions
Biodesix Inc	1.09	$ 18.987 Millions	$ 17.436 Millions
Medpace Holdings Inc	1.02	$ 497.049 Millions	$ 489.358 Millions
Advanced Biomed Inc.	0.95	$ 2.608 Millions	$ 2.747 Millions
Lumexa Imaging Holdings Inc	0.60	$ 58.828 Millions	$ 98.015 Millions
Fortrea Holdings Inc	0.41	$ 174.600 Millions	$ 430.300 Millions
Koninklijke Philips Nv	0.37	$ 3,196.480 Millions	$ 8,563.520 Millions
Iqvia Holdings Inc	0.34	$ 2,141.000 Millions	$ 6,220.000 Millions
Mdxhealth Sa	0.34	$ 29.032 Millions	$ 86.527 Millions

Date modified: 2026-06-22T16:30:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.